Simone Bido RicercatoreMedicina
The 1% of the population above 60 is affected by Parkinson’s disease (PD) worldwide. PD is characterized by motor and cognitive impairments caused by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. Even though the clinical manifestation of PD is well described, the pathophysiological mechanisms underlying PD ethology remains not fully understood. The reason for this uncertainty lies in the multifactorial nature of the disease which includes genetic factors, environmental triggers, and aging. For this reason, a precise and accurate description of the contribution of the different factors to the disease development is of paramount importance to design a personalized disease-modifying therapies.
Our laboratory has a great expertise in the field of PD and related disorders thanks to the development of a variety of different animal models which allow us to recapitulate the salient and unique aspect observable in human patients. These tools, together with the use of high throughput analysis, enable us to dissect the contribution of different mechanisms in the onset of the disease, which permits the design of novel and specific gene therapy strategies.
December 2010 / March 2013: PhD in Pharmacology, Università degli Studi di Ferrara, Ferrara, Italy
September 2003 / March 2009: Master degree in Medicinal Chemistry; Università degli Studi di Ferrara, Ferrara, Italy
2021 – present: Researcher at Ospedale San Raffaele, Stem Cell and Neurogenesis Unit, Milan, Italy
2016 - 2021: Post Doc at the Ospedale San Raffaele in the laboratory of Stem Cell and Neurogenesis, Milan, Italy
2014: Visiting Post Doc at the University of Pennsylvania, Philadelphia, USA
2013 - 2016: Post Doc at the Institut des Maladies Neurodégénératives (IMN), Bordeaux, France
2009 - 2010: Project management of the NODYSK project, Ferrara, Italy
2008 - 2009: visiting student at the Karolinska Institutet in Stockholm, Sweden
- “Early Career Award” Fondazione Regionale per la Ricerca Biomedica (FRRB), Regione Lombardia (March 2021).
- Michel J Fox Foundation, Dyskinesia Challenge 2013 (September 2013).
- IBRO InEurope grant (May, 2013).
- Spinner 2013, Regione Emilia Romagna (July 2009).
1- Faivre F, Sánchez-Catalán MJ, Dovero S, Bido S, Joshi A, Bezard E, Barrot M. Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease. Neurobiol Dis. 2020 Feb; 139:104818. IF: 5.2
2- Iannielli A, Ugolini GS, Cordiglieri C, Bido S, Rubio A, Colasante G, Valtorta M, Cabassi T, Rasponi M, Broccoli V. Reconstitution of the Human Nigro-striatal Pathway on-a-Chip Reveals OPA1-Dependent Mitochondrial Defects and Loss of Dopaminergic Synapses. Cell Reports. 2019 Dec; 29:4646-4656. IF: 7.8
3- Colasante, G, Lignani G, Brusco S, Di Berardino C, Carpenter J, Giannelli S, Valassina N, Bido S, Ricci R, Castoldi V, Marenna S, Church T, Massimino L, Morabito G, Benfenati F, Schorge S, Leocani L, Kullmann DM, Broccoli V. dCas9-based Scn1a gene activation restores inhibitory interneuron excitability and attenuates seizures in Dravet syndrome mice. Molecular Therapy 2019 Jan:1(28):1-19. IF: 8.4
4- Bido S*, Iannielli A*, Folladori L, Segnali A, Cancellieri C, Maresca A, Massimino L, Rubio A, Morabito G, Caporali L, Tagliavini F, Musumeci O, Gregato G, Bezard E, Carelli V, Tiranti V, Broccoli V. Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson’ s Disease Models. Cell Reports 2018 Feb:8(22):2066-79. IF: 8.032
5- Morabito G, Giannelli SG, Ordazzo G, Bido S, Castoldi V, Indrigo M, Cabassi T, Cattaneo S, Luoni M, Cancellieri C, Sessa A, Bacigaluppi M, Taverna S, Leocani L, Lanciego JL, Broccoli V.
AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy. Mol. Ther. 2017 Aug: S1525-0016 IF: 8.4
6- Bido S, Soria FN, Fan RZ, Bezard E, Tieu K. Mitochondrial division inhibitor-1 is neuroprotective in A53T -α-synuclein rat model of Parkinson’s disease Sci. Rep. 2017 Aug:7(1)-7495. IF: 4.1
7- Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiol Dis. 2016 May;89:55-64. IF: 5.0
8- Bastide MF, Bido S, Duteil N, Bézard E. Striatal NELF-mediated RNA polymerase II stalling controls l-dopa induced dyskinesia Neurobiol Dis. 2015 Oct 19;85:93-98. IF: 5.2
9- Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N, Vollenweider I, Baud L, Piron C, Grouthier V, Boraud T, Porras G, Li Q, Baekelandt V, Scheller D, Michel A, Fernagut PO, Georges F, Courtine G, Bezard E, Dehay B. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathol Commun. 2015 Jul;25;3:46. IF: 5.8
10- Bido S, Solari N, Indrigo M, D'Antoni A, Brambilla R, Morari M, Fasano S. Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia. Ann Clin Transl Neurol. 2015 Jun;2:662-78. IF:4.6
11- Barroso-Chinea P, Thiolat ML, Bido S, Martinez A, Doudnikoff E, Baufreton J, Bourdenx M, Bloch B, Bezard E, Martin-Negrier ML. D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly. Neurobiol Dis. 2015 Jun;78:77-87 IF: 5.0
12- Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG.
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Proc Natl Acad Sci. 2015 May;12;112 IF:9.7
13- Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, Drechsler M, Mazzoni S, Menegatti E, Morari M, Cortesi R. Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm. 2012 Feb;80:306-14. IF:4.7
14- Mela F, Marti M, Bido S, Cenci MA, Morari M. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol Dis. 2012 Jan;45:573-82. IF: 5.0
15- Bido S, Marti M, Morari M. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem. 2011 Sep;118:1043-55. IF: 4.6
16- Volta M, Mabrouk OS, Bido S, Marti M, Morari M. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. J Neurochem. 2010 Dec;115:1543-55. IF: 4.0
Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.